Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through following segments: Platform and Product. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.